NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Closed 03-23 16:00:00 EDT

11.82

+0.01

+0.08%

盘后12.05

+0.23+1.95%

19:16 EDT

High12.19	Low11.63	Vol1.55M
Open11.94	D1 Closing11.81	Amplitude4.75%
Mkt Cap1.35B	Tradable Cap1.11B	Total Shares114.00M
T/O18.36M	T/O Rate1.64%	Tradable Shares94.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":11.82,"timestamp":1774296000000,"preClose":11.81,"halted":0,"volume":1545034,"hourTrading":{"tag":"盘后","latestPrice":12.05,"preClose":11.82,"latestTime":"19:16 EDT","volume":281688,"amount":3329652.83,"timestamp":1774307792144,"change":0.23,"changeRate":0.019459,"amplitude":0.019459},"delay":0,"changeRate":0.0008467400508043849,"floatShares":94147892,"shares":113999999,"eps":-1.222073,"marketStatus":"Closed","change":0.01,"latestTime":"03-23 16:00:00 EDT","open":11.94,"high":12.19,"low":11.6287,"amount":18360491.880768,"amplitude":0.047528,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.222073,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774339200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":11.81,"preHourTrading":{"tag":"盘前","latestPrice":11.94,"preClose":11.81,"latestTime":"08:59 EDT","volume":230,"amount":2785.82003,"timestamp":1774270797952,"change":0.13,"changeRate":0.011008,"amplitude":0.051651},"postHourTrading":{"tag":"盘后","latestPrice":12.05,"preClose":11.82,"latestTime":"19:16 EDT","volume":281688,"amount":3329652.83,"timestamp":1774307792144,"change":0.23,"changeRate":0.019459,"amplitude":0.019459},"volumeRatio":1.179327,"impliedVol":1.1251,"impliedVolPercentile":0.9004},"requestUrl":"/m/hq/s/NVCR","defaultTab":"news","newsList":[{"id":"2618604979","title":"Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604979","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618604979?lang=en_us&edition=fundamental","pubTime":"2026-03-10 09:15","pubTimestamp":1773105311,"startTime":"0","endTime":"0","summary":"In early March 2026, NovoCure reported that Japan’s Ministry of Health, Labour and Welfare approved National Health Insurance reimbursement for Optune Lua for adults with unresectable advanced or recurrent non-small cell lung cancer progressing after platinum-based chemotherapy.\nThis milestone not only broadens access to NovoCure’s Tumor Treating Fields technology in a key oncology market, but also adds a new reimbursed indication to support its growing therapy ecosystem.\nNext, we’ll explore...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/should-japans-optune-lua-reimbursement-win-reframe-novocures","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/should-japans-optune-lua-reimbursement-win-reframe-novocures","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4534","NVCR","BK4585","BK4588","BK4082","BK4548"],"gpt_icon":0},{"id":"2616350754","title":"NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2616350754","media":"Simply Wall St.","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616350754?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:20","pubTimestamp":1772468424,"startTime":"0","endTime":"0","summary":"In late February 2026, NovoCure reported fourth-quarter 2025 revenue of US$174.35 million and a quarterly loss of US$24.5 million, alongside full-year 2025 revenue of US$655.35 million and a narrowed annual loss of US$136.23 million, while issuing 2026 net revenue guidance of US$675 million to US$705 million.\nAlongside these results, NovoCure secured U.S. FDA approval and began the commercial launch of Optune Pax for locally advanced pancreatic cancer, signaling a shift from a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-is-up-245-after-fda-approval-of-optune-pax-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-is-up-245-after-fda-approval-of-optune-pax-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NVCR","BK4588","BK4082","BK4534","BK4548","BK4585"],"gpt_icon":0},{"id":"2616339084","title":"Japan approves national reimbursement for Novocure's Optune Lua in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339084","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339084?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452830,"startTime":"0","endTime":"0","summary":"Novocure Ltd. said Japan’s Ministry of Health, Labour and Welfare approved national reimbursement for Optune Lua under the country’s National Health Insurance coverage. The device is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer who progressed on or after platinum-based chemotherapy. Novocure said it plans to launch Optune Lua in Japan with reimbursement coverage.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL9CqkmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4082","BK4588","BK4585","NVCR","BK4548"],"gpt_icon":0},{"id":"2616933180","title":"Novocure Ltd - Optune Lua Approved for Use With Pd-1/Pd-L1 Inhibitors in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2616933180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616933180?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA9S9Z80:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4548","BK4585","BK4588","NVCR","BK4534"],"gpt_icon":0},{"id":"2616339757","title":"Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339757?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA9S9Z80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4588","BK4082","BK4548","NVCR","BK4585"],"gpt_icon":0},{"id":"2616318893","title":"Novocure Ltd - to Launch Optune Lua in Japan With Reimbursement","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616318893?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA9S9Z80:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCR","BK4548","BK4588","BK4534","BK4082","BK4585"],"gpt_icon":0},{"id":"2616870450","title":"NovoCure Earnings Call: Growth Builds Amid Profit Strain","url":"https://stock-news.laohu8.com/highlight/detail?id=2616870450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616870450?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:27","pubTimestamp":1772411228,"startTime":"0","endTime":"0","summary":"NovoCure Ltd. (($NVCR)) has held its Q4 earnings call. Read on for the main highlights of the call. NovoCure’s latest earnings call struck a cautio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novocure-earnings-call-growth-builds-amid-profit-strain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novocure-earnings-call-growth-builds-amid-profit-strain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCR"],"gpt_icon":0},{"id":"2614867302","title":"Novocure to Participate in Leerink Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614867302","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614867302?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:30","pubTimestamp":1772227823,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire  on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL85mXfH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4082","BK4588","NVCR","BK4585","BK4534"],"gpt_icon":0},{"id":"2614020993","title":"Novocure Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614020993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614020993?lang=en_us&edition=fundamental","pubTime":"2026-02-27 02:58","pubTimestamp":1772132280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 13:58 ET (18:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4585","BK4588","BK4082","BK4534","BK4548"],"gpt_icon":0},{"id":"2614281740","title":"Novocure Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614281740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614281740?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:32","pubTimestamp":1772116331,"startTime":"0","endTime":"0","summary":"Novocure Ltd reports results for the quarter ended December 31 - Earnings SummaryNovocure Ltd NVCR.OQ reported a quarterly adjusted loss of 22 cents per share for the quarter ended December 31, higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL8N3ZM1W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","NVCR","BK4588","BK4082","BK4534"],"gpt_icon":0},{"id":"1124858099","title":"Stock Track | NovoCure Plunges 7.4% Pre-Market on Margin Pressure and Weak EBITDA Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1124858099","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124858099?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:07","pubTimestamp":1772111225,"startTime":"0","endTime":"0","summary":"NovoCure's stock experienced a significant pre-market plunge of 7.40% on Thursday. The sharp decline followed the release of the company's fourth-quarter 2025 financial results and its guidance for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVCR"],"gpt_icon":0},{"id":"2614049363","title":"Earnings Flash (NVCR) Novocure Reports Q4 Loss $0.22 a Share, vs. FactSet Est of $0.41 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2614049363","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614049363?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:27","pubTimestamp":1772108872,"startTime":"0","endTime":"0","summary":"Earnings Flash (NVCR) Novocure Reports Q4 Loss $0.22 a Share, vs. FactSet Est of $0.41 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"gpt_icon":0},{"id":"2614046083","title":"Novocure Q4 revenue slightly beats expectations, margins drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046083","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046083?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:21","pubTimestamp":1772108513,"startTime":"0","endTime":"0","summary":"Novocure Q4 revenue slightly beats expectations, margins dropOverviewOncology company's Q4 revenue slightly beat analyst expectationsAdjusted EBITDA for Q4 was negative, reflecting investments in clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4534","BK4588","BK4548","BK4585","NVCR"],"gpt_icon":0},{"id":"2614467530","title":"Novocure Q4 Revenue USD 174.35 Million Vs. IBES Estimate USD 173.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614467530","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614467530?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:18","pubTimestamp":1772108289,"startTime":"0","endTime":"0","summary":"Feb 26 (Reuters) - Novocure Q4 gross profit USD 132.193 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 26-FEB-202612:00:48.83 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nRSD33c8lg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4534","BK4548","BK4585","BK4082","NVCR"],"gpt_icon":0},{"id":"2614045118","title":"Novocure Q4 net loss hits USD 24.5 million as R&D spending rises 19% to USD 60.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045118","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045118?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:01","pubTimestamp":1772107309,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire  on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL9YjCJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4548","BK4588","BK4082","NVCR","BK4585"],"gpt_icon":0},{"id":"2614614045","title":"Novocure Q4 Pretax Profit USD -40.954 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614614045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614614045?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX182BD3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","NVCR","BK4082","BK4534","BK4585","BK4588"],"gpt_icon":0},{"id":"2614468930","title":"Novocure Ltd: Outlook 2026 Adj Ebitda $-20 Mln - $0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614468930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614468930?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX182BD3:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4082","BK4588","BK4585","NVCR","BK4548"],"gpt_icon":0},{"id":"2614045058","title":"Novocure Ltd - 2026 Revenue Guidance $675 Mln-$705 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045058?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX182BD3:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4534","BK4588","NVCR","BK4585","BK4548"],"gpt_icon":0},{"id":"2614889428","title":"Today’s Market Recap: AI Momentum Lifts U.S. Markets as Tariff Battles and Global Trade Tensions Unfold","url":"https://stock-news.laohu8.com/highlight/detail?id=2614889428","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614889428?lang=en_us&edition=fundamental","pubTime":"2026-02-26 08:37","pubTimestamp":1772066237,"startTime":"0","endTime":"0","summary":"This recap highlights how U.S. markets gained momentum on February 25, 2026, driven by strong enthusiasm for artificial intelligence and Nvidia’s earnings beat, while other tech names followed suit. It also covers Trump’s State of the Union address, tariff developments, and global trade tensions inv","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20260120/TradingKey_-EN_optimized_150-af50e3d803094b2981fdc0ce98cb441f.png","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260120/TradingKey_-EN_optimized_150-af50e3d803094b2981fdc0ce98cb441f.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261622025-market-recap-ai-momentum-tariff-global-trade-tensions-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983260115.SGD","IE0004445015.USD","LU1868836914.USD","LU1861215975.USD","IE00BMPRXQ63.HKD","LU2458330169.SGD","LU0882574139.USD","LU2452424414.USD","LU2065171311.SGD","BK4534","LU1429558221.USD","LU0965509010.AUD","HK0000914686.HKD","LU1211504680.USD","LU1508157978.USD","LU2125154935.USD","LU1629891620.HKD","LU0079474960.USD","3NVD.UK","LU0256863902.USD","LU2294711713.HKD","BK4598","LU0094547139.USD","IE00BDRTCR15.USD","IE00BN29S564.USD","SG9999014559.SGD","BK4548","BK4526","LU1868838027.USD","LU0170899867.USD","IE0009G5SDU7.USD","LU1145028129.USD","LU1861220033.SGD","LU1323610961.USD","LU2247934214.USD","LU2357125470.USD","SG9999014542.SGD","HK0000320264.USD","LU2168564149.EUR","LU1778281490.HKD","LU2361044865.SGD","LU0310800379.SGD","IE00BYXW3230.USD","LU1691799644.USD","LU2211815571.USD","BK4082","LU0323591593.USD","IE00BWXC8680.SGD","SGXZ99366536.SGD","LU1989764664.SGD","LU1951200564.SGD","BK4528","LU1923622291.USD","SG9999018865.SGD","IE0034235188.USD","LU0648001328.SGD","LU0265550359.USD","LU0096364046.USD","IE0034235303.USD","LU1366333091.USD","LU1366192091.USD","NVDX","LU0708995401.HKD","LU2462157665.USD","LU2125909593.SGD","BK4532","LU2265009873.SGD","LU0225283273.USD","LU0957808578.USD","LU0198837287.USD","LU0130517989.USD","IE00B19Z9505.USD","LU2242649171.HKD","LU0878005551.USD","LU1992135472.HKD","TSMU","LU2491049909.HKD","LU0069063385.USD","LU2931357623.SGD","LU1551013425.SGD","LU1989772923.USD","BK4550","LU0384037296.USD","LU0942090050.USD","LU2191332357.HKD","LU2213496289.HKD","LU0048584097.USD","LU0203202063.USD","SG9999015341.SGD","LU0107464264.USD","LU2430703095.HKD","LU2552382058.USD","LU1814569148.SGD","LU1868837565.USD","IE00B3SWFQ91.USD","LU2041044095.USD","IE00B4YYXB79.USD","LU0787776722.HKD","IE0004445239.USD","LU2322448791.USD","BK4613","BK4503","IE00BJTD4N35.SGD","LU2298321311.HKD","LU1201861249.SGD","LU0109392836.USD","LU1935043023.USD","SG9999017495.SGD","LU1244550577.SGD","HK0000306701.USD","LU2271345857.HKD","LU2063271972.USD","LU0708994859.HKD","LU0308772762.SGD","LU0823434740.USD","LU1721428933.USD","LU0210533765.USD","LU0541501648.USD","LU0719512351.SGD","LU0048573561.USD","BK4023","LU0096362180.USD","LU0210528500.USD","LU1992135399.USD","LU1116320737.USD","LU0820561909.HKD","LU0061474705.USD","IE00BKVL7J92.USD","LU0889566641.SGD","LU1153585028.USD","LU0889565833.HKD","LU2505996509.AUD","LU0128525689.USD","LU0082616367.USD","NVDB","LU2458330243.SGD","LU1232071149.USD","SG9999015986.USD","LU0215105999.USD","LU2089985449.USD","LU2456880835.USD","BK4587","LU0943347566.SGD","SGXZ23171101.USD","LU0203347892.USD","LU2471134879.HKD","LU0070217475.USD","BK4538","LU2250418816.HKD","LU2506951792.HKD","IE00B775SV38.USD","SG9999004303.SGD","NVDS.UK","LU0976567544.SGD","LU1988902786.USD","LU2471134796.USD","LU2087625088.SGD","LU2236285917.USD","LU0320765059.SGD","BK4529","IE00BFXG0V08.USD","LU0234572021.USD","LU1066051498.USD","IE00BHPRN162.USD","IE00BKDWB100.SGD","LU1674673428.USD","LU0154236417.USD","LU2357305700.SGD","LU2168564222.USD","LU0057025933.USD","LU0266013472.USD","LU0724617625.USD","LU1496350502.SGD","LU0348723411.USD","LU1633808545.USD","IE000W1ABFV2.USD","LU2750360997.AUD","IE0009356076.USD","NVDD","IE00B19Z3B42.SGD","LU0006306889.USD","LU2602419157.SGD","LU1868837136.USD","SG9999000418.SGD","LU1316542783.SGD","LU2028103732.USD","LU2360108059.USD","LU1282649810.SGD","LU2125154778.USD","SG9999002232.USD","BK4533","LU1934455277.USD","LU0345770308.USD","IE00BKPKM429.USD","LU0289960550.SGD","NVDG","LU2054465674.USD","NVII","LU0861579265.USD","LU0211326755.USD","BK4561","IE00BZ199S13.USD","LU2065171402.SGD","LU2505996681.GBP","IE0005OL40V9.USD","LU1119994496.HKD","BK4579","LU0072462426.USD","LU2111349929.HKD","LU2249611893.SGD","SG9999015358.SGD","LU2048586759.USD","LU0494093205.USD","LU1242518857.USD","LU2491050071.SGD","LU0823421416.USD","LU0868494617.USD","LU2097344357.USD","IE0034235295.USD","LU0472753341.HKD","LU2125909759.SGD","LU0444971666.USD","LU1935043536.SGD","LU2133065610.SGD","IE0004091025.USD","LU0964807845.USD","LU2592432038.USD","LU2290526834.HKD","IE00B19Z3581.USD","LU0080751232.USD","CRMG","LU2433249047.HKD","LU0310800965.SGD","IE00BMPRXR70.SGD","LU1267930227.SGD","TSMY","IE00B7KXQ091.USD","LU1267930490.SGD","LU1571399168.USD","LU2487616109.SGD","LU1242518931.SGD","BK4551","LU0128525929.USD","IE00BYQQ9H92.USD","LU1037948541.HKD","LU0353189680.USD","LU2089284900.SGD","LU2237443382.USD","SNVD.UK","NVDU","LU1720051017.SGD","BK4553","LU0061475181.USD","LU0342679015.USD","LU1951198990.SGD","LU2361045086.USD","LU2896262040.SGD","LU0251132253.USD","IE00BDCRKT87.USD","LU0097036916.USD","LU0345768153.USD","LU2023250504.SGD","LU2237443978.SGD","HK0000306685.HKD","LU1023057109.AUD","LU0143863784.USD","BK4170","IE00BJLML261.HKD","LU0689626769.HKD","BK4543","LU0289739343.SGD","LU0878004406.USD","LU0345769631.USD","NVIW.SI","LU0056508442.USD","LU1261432733.SGD","LU2430703178.SGD","MUD","IE000KEQY171.SGD","LU0957791311.USD","LU1623119135.USD","LU0823414551.USD","IE00BJTD4V19.USD","BK4608","IE00BQXX3D17.EUR","LU2463028550.USD","LU0985320562.USD","SG9999014880.SGD","LU2237957811.SGD","LU2092937221.SGD","SGXZ31699556.SGD","LU0029864427.USD","LU0264606111.USD","NVD3.UK","LU0359201885.HKD","LU0052756011.USD","LU2023251221.USD","BK4591","LU2168564495.EUR","IE00BFSS7M15.SGD","LU2211814178.USD","LU2413666699.HKD","LU1496350171.SGD","LU1923622614.USD","LU2326559502.SGD","LU0359202008.SGD","LU1244550494.USD","LU0965509283.SGD","2NVD.UK","LU1267930813.SGD","LU0572939691.SGD","LU1815336760.USD","LU0882747503.HKD","SG9999015945.SGD","STSM","LU1280957306.USD","LU2089283258.USD","LU1989772840.SGD","BK4549","NVDA","LU2264538146.SGD","LU2756315664.SGD","LU0211328371.USD","LU0642271901.SGD","LU0053666078.USD","BK4575","LU2420271590.USD","LU0672654240.SGD","IE00B3M56506.USD","LU1699723380.USD","NVD2.UK","BK4141","LU0211327993.USD","LU2746668461.USD","LU2361044949.HKD","LU0496365809.HKD","LU1069344957.HKD","LU2092937148.SGD","LU0124676726.USD","SG9999015978.USD","IE00BZ1G4Q59.USD","LU1282649067.USD","LU1035775433.USD","SG9999014914.USD","IE00BD6J9T35.USD","LU0345769128.USD","LU0157215616.USD","LU0106261372.USD","SG9999002224.SGD","SG9999018857.SGD","LU1235294995.USD","LU0823434583.USD","LU0488056044.USD","HK0000914660.USD","LU0077335932.USD","BK4605","IE00B3S45H60.SGD","LU2552382215.SGD","BK7142","LU0823414478.USD","IE00B5949003.HKD","LU2108987350.USD","SG9999014906.USD","LU1267930730.SGD","LU1712237335.SGD","TSMX","LU1974910355.USD","LU1037948897.HKD","SGXZ81514606.USD","NVDS","LU1084165304.USD","LU0127658192.USD","LU0683600562.USD","GB00BDT5M118.USD","BK4567","LU0476273544.USD","IE0004086264.USD","BK4585","LU0640476718.USD","BK4566","BK4527","LU0528227936.USD","LU1267930573.SGD","LU2087621335.USD","LU0011850046.USD","BK4592","LU0444973449.USD","LU1821325948.USD","MULL","IE00BJJMRX11.SGD","LU1244550221.USD","LU2272731600.USD","LU1914381329.SGD","LU0256863811.USD","ANV","BK4554","IE00B19Z8X17.USD","LU0359201612.USD","LU2552382132.HKD","BK4581","IE000ITXATA3.USD","IE00BFSS8Q28.SGD","LU0511384066.AUD","IE0003U64NQ7.SGD","LU2272731865.HKD","LU1127390331.HKD","IE0001KFT4U8.USD","BK4614","LU0466842654.USD","LU1791710582.SGD","LU0980610538.SGD","SG9999014898.SGD","LU1935042215.USD","03145","SG9999004220.SGD","LU0965509101.SGD","TSMG","NVDY","LU0541502299.USD","LU1823568750.SGD","LU0310799852.SGD","NVD","LU0267386448.USD","LU2413666426.HKD","LU0211326839.USD","LU0158827781.USD","LU0316494557.USD","NVCR","LU0477156953.USD","LU2471134952.CNY","LU1989764748.USD","LU2360032135.SGD","LU0354030438.USD","LU2097344431.USD","LU2491050154.USD","LU1852331112.SGD","LU2244417387.USD","LU0276348264.USD","LU0251142724.SGD","IE00B775H168.HKD","LU0203345920.USD","LU1868837722.USD","LU1934455863.HKD","IE00BQXX3F31.USD","BK4515","LU0143863198.USD","LU0979878070.USD","LU2272731782.SGD","LU2746668974.SGD","SGXZ51526630.SGD","IE00B1XK9C88.USD","LU2322448957.HKD","IE00B5TLWC47.USD","LU0786609619.USD","LU1935042488.USD","BK4584","LU2242650005.HKD","IE00BK4W5M84.HKD","LU2168564065.EUR","LU1935042991.SGD","LU1868837300.USD","LU1861127337.USD","LU2168563687.JPY","LU0868494708.USD","LU0238689110.USD","DLLL","LU0210536198.USD","BK4607","LU0265550946.USD","LU2403377893.USD","LU2065170008.USD","LU1923623000.USD","LU2065169927.USD","LU2106854487.HKD","LU1804176565.USD","LU2663582299.SGD","LU1868836757.USD","SG9999014567.USD","LU2430703251.USD","LU1815333072.USD","LU0417517546.SGD","LU0557290698.USD","LU0965508806.USD","LU1548497426.USD","HK0000320223.HKD","LU2237443622.USD","LU0742534661.SGD","LU0347712357.USD","LU0234570918.USD","SG9999015952.SGD","LU2360106780.USD","LU2083900584.USD","LU2092627202.USD","LU1046421795.USD","LU0251131958.USD","LU1116320901.HKD","IE00BK4W5L77.USD","LU1718418525.SGD","IE00BMPRXN33.USD","NVDQ","LU0130102774.USD","LU1642822529.SGD","LU1868836591.USD","LU1720051108.HKD","BK4512","LU0158827948.USD","LU0788109477.HKD","BK4535","LU2543165471.USD","LU1934455194.USD","LU2237443549.SGD","LU2417539215.USD","LU2237957902.USD","LU0792757196.USD","BK4602","LU1674673691.USD","LU2471134523.USD","NVDW","LU2237438978.USD","BK4612","LU1791710400.SGD","LU2286300806.USD","LU1066051225.USD","LU2750360641.GBP","LU0061474960.USD","LU0823421333.USD","LU1839511570.USD","IE00B4JS1V06.HKD","IE00BJJMRY28.SGD","IE00B7SZLL34.SGD","LU1064131342.USD","SG9999014575.USD","LU0203201768.USD","LU2461242641.AUD","LU1551013342.USD","BK4588","LU0175139822.USD","IE00B1BXHZ80.USD","LU1066053197.SGD","LU2381873111.SGD","TSM","LU0289961442.SGD","LU0109391861.USD","IE0002270589.USD","LU0353189763.USD","SG9999001424.SGD","LU0689472784.USD","LU2360107168.USD","LU0820562030.AUD","LU1066051811.HKD","LU2125909916.SGD","LU2473716301.USD","LU0081259029.USD","IE000YTNTUN2.SGD","LU2756315318.SGD","LU2860962120.EUR","LU2023250330.USD","LU1435385759.SGD","LU2125909247.SGD","BK4139","LU0345768740.USD","LU0820561818.USD","IE00B19Z8W00.USD","LU0187121727.USD","LU1803068979.SGD","LU0572940350.SGD","LU2077746001.SGD","LU0390134368.USD","LU0345770993.USD","TSMZ","LU1917777945.USD","DIPS","IE00BQXX3C00.GBP","MNKD","LU0354030511.USD","BK4505","LU0274383776.USD"],"gpt_icon":1},{"id":"2614343058","title":"NovoCure Up Over 27%, On Pace for Largest Percent Increase Since December 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2614343058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614343058?lang=en_us&edition=fundamental","pubTime":"2026-02-26 03:03","pubTimestamp":1772046180,"startTime":"0","endTime":"0","summary":"NovoCure Ltd.  is currently at $14.94, up $3.20 or 27.21%. --Would be highest close since July 23, 2025, when it closed at $16.51. --On pace for largest percent increase since Dec. 2, 2024, when it rose 48.95%. --Currently up two consecutive days; up 36.02% over this period. --Up 20.44% month-to-date; on pace for best month since Dec. 2024, when it rose 48.7%. --Down 93.38% from its all-time closing high of $225.58 on June 23, 2021. --Down 31.99% from 52 weeks ago , when it closed at $21.96. --Up 48.9% from its 52-week closing low of $10.03 on Feb. 9, 2026. --Up 31.69% at today's intraday high; largest intraday percent increase since Feb. 12, 2026, when it rose as much as 42.57%","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4548","BK4082","BK4585","BK4534","NVCR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0693},{"period":"1year","weight":-0.3843},{"period":"ytd","weight":-0.0866}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.026321},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.001726},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.028453},{"month":4,"riseRate":0.5,"avgChangeRate":0.079553},{"month":5,"riseRate":0.8,"avgChangeRate":0.134604},{"month":6,"riseRate":0.4,"avgChangeRate":-0.026837},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004605},{"month":8,"riseRate":0.6,"avgChangeRate":0.019977},{"month":9,"riseRate":0.4,"avgChangeRate":-0.021376},{"month":10,"riseRate":0.2,"avgChangeRate":-0.091688},{"month":11,"riseRate":0.636364,"avgChangeRate":0.077306},{"month":12,"riseRate":0.545455,"avgChangeRate":0.065178}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}